Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)

To evaluate the efficacy of azelnidipine and amlodipine on diabetic nephropathy and atherosclerosis, we designed a prospective and randomized controlled clinical study in type 2 diabetic patients with stable glycemic control with fixed dose of anti-diabetic medication. Although there was no differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawaramoto, Kazuhito, Kaneto, Hideaki, Hashiramoto, Mitsuru, Kawasaki, Fumiko, Tatsumi, Fuminori, Shimoda, Masashi, Kamei, Shinji, Matsuki, Michihiro, Mune, Tomoatsu, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574138/
https://www.ncbi.nlm.nih.gov/pubmed/26388951
http://dx.doi.org/10.1186/s13098-015-0073-9
_version_ 1782390576804528128
author Tawaramoto, Kazuhito
Kaneto, Hideaki
Hashiramoto, Mitsuru
Kawasaki, Fumiko
Tatsumi, Fuminori
Shimoda, Masashi
Kamei, Shinji
Matsuki, Michihiro
Mune, Tomoatsu
Kaku, Kohei
author_facet Tawaramoto, Kazuhito
Kaneto, Hideaki
Hashiramoto, Mitsuru
Kawasaki, Fumiko
Tatsumi, Fuminori
Shimoda, Masashi
Kamei, Shinji
Matsuki, Michihiro
Mune, Tomoatsu
Kaku, Kohei
author_sort Tawaramoto, Kazuhito
collection PubMed
description To evaluate the efficacy of azelnidipine and amlodipine on diabetic nephropathy and atherosclerosis, we designed a prospective and randomized controlled clinical study in type 2 diabetic patients with stable glycemic control with fixed dose of anti-diabetic medication. Although there was no difference in blood pressure between both groups, urinary albumin excretion and maximum carotid intima-media thickness were reduced in azelnidipine group, but not in amlodipine group. In addition, inflammatory cytokine levels were decreased only in azelnidipine group which possibly explains such beneficial effects of azelnidipine on urinary albumin excretion and carotid atherosclerosis.
format Online
Article
Text
id pubmed-4574138
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45741382015-09-19 Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study) Tawaramoto, Kazuhito Kaneto, Hideaki Hashiramoto, Mitsuru Kawasaki, Fumiko Tatsumi, Fuminori Shimoda, Masashi Kamei, Shinji Matsuki, Michihiro Mune, Tomoatsu Kaku, Kohei Diabetol Metab Syndr Letter to the Editor To evaluate the efficacy of azelnidipine and amlodipine on diabetic nephropathy and atherosclerosis, we designed a prospective and randomized controlled clinical study in type 2 diabetic patients with stable glycemic control with fixed dose of anti-diabetic medication. Although there was no difference in blood pressure between both groups, urinary albumin excretion and maximum carotid intima-media thickness were reduced in azelnidipine group, but not in amlodipine group. In addition, inflammatory cytokine levels were decreased only in azelnidipine group which possibly explains such beneficial effects of azelnidipine on urinary albumin excretion and carotid atherosclerosis. BioMed Central 2015-09-17 /pmc/articles/PMC4574138/ /pubmed/26388951 http://dx.doi.org/10.1186/s13098-015-0073-9 Text en © Tawaramoto et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Tawaramoto, Kazuhito
Kaneto, Hideaki
Hashiramoto, Mitsuru
Kawasaki, Fumiko
Tatsumi, Fuminori
Shimoda, Masashi
Kamei, Shinji
Matsuki, Michihiro
Mune, Tomoatsu
Kaku, Kohei
Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
title Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
title_full Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
title_fullStr Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
title_full_unstemmed Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
title_short Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
title_sort azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in type 2 diabetes (boat2 study)
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574138/
https://www.ncbi.nlm.nih.gov/pubmed/26388951
http://dx.doi.org/10.1186/s13098-015-0073-9
work_keys_str_mv AT tawaramotokazuhito azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT kanetohideaki azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT hashiramotomitsuru azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT kawasakifumiko azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT tatsumifuminori azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT shimodamasashi azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT kameishinji azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT matsukimichihiro azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT munetomoatsu azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study
AT kakukohei azelnidipinebutnotamlodipinereducesurinaryalbuminexcretionandcarotidatherosclerosisinsubjectswithtype2diabetesbloodpressurecontrolwitholmesartanandazelnidipineintype2diabetesboat2study

Ejemplares similares